Abstract. Cluster of differentiation (CD)68 may be used as a pan-macrophage or M1 marker, whereas CD163 may be used as an M2 marker. Furthermore, folate receptor (FR)β exhibits an M2-like functional profile. In the present study, CD68 and CD163 were used to evaluate and classify tumor-associated macrophages (TAMs). The expression of CD68, CD163 and FRβ by TAMs in hepatocellular carcinoma (HCC) Tissues was investigated. Samples from 105 patients with HCC were evaluated using immunohistochemistry. The results revealed that CD68 and CD163 overexpression was associated with a worse prognosis. The number of CD68 positive cells observed was significantly higher in patients with stage IV cancer. Furthermore, an increase in CD68 positive cells was observed in patients with median tumor size ≥3.5 cm and in patients with poorly differentiated HCC. The number of CD163 positive cells was also significantly increased in patients with median tumor size ≥3.5 cm and in those with poorly differentiated HCC. A low CD163/68 ratio was correlated with a worse outcome. The ratio was significantly lower in patients with stage IV cancer, patients with des-gamma-carboxy prothrombin abnormalities, patients with blood vessel infiltration and patients with intrahepatic metastasis. The number of FRβ positive cells was not correlated with clinicopathological features. The results of the present study indicate that overexpression of CD68 and CD163 may be associated with a worse patient outcome. The evaluation of CD68 and CD163 positive cells in a cancer microenvironment is controversial. TAMs are not simply cells with single markers or restricted M1 or M2 phenotypes; they are more diverse and heterogeneous. Further studies are required to determine the cross-interaction between diverse TAMs and the tumor microenvironment.
Introduction
Hepatocellular carcinoma (HCC) is the most common liver cancer (1) . Currently, HCC is the third most deadly and fifth most common cancer worldwide (1, 2) . Chronic infection with hepatitis B virus, which affects ~5% of the global population, or hepatitis C virus (HCV), affecting which affects 2% of the global population, is a risk factor for the development of HCC (3) . In Japan, a large number of patients are infected with hepatitis and, in 2008, HCC was the fourth most deadly and the sixth most common cancer in Japan (4) .
It has been reported that inflammation serves important roles in tumorigenesis. A number of environmental causes and risk factors for cancer are associated with certain forms of chronic inflammation; it has been suggested that ≤20% of cancers, including HCC, are linked to chronic infections (5) . Chronic inflammation has long been associated with an increased incidence of malignancy and similarities in regulatory mechanisms have been suggested. The infiltration of innate immune cells, including macrophages and neutrophils, into tumors promotes tumor development via various mechanisms (5) . Tumor-associated macrophages (TAMs) are associated with myeloid-derived suppressor cells and are key prototypic components of inflammation that drive neoplastic progression (6) . It is known that solid tumors are generally infiltrated by macrophages (7) . Studies have revealed that a high degree of macrophage infiltration is associated with poor prognosis for a number of human malignancies, including hepatocellular, colon, breast and lung carcinoma, and brain gliomas (7) (8) (9) (10) (11) (12) .
Polarized M1 and M2 macrophages represent the extremes of a continuum of functional states for TAMs. The classically activated M1 macrophages are potent effector cells that kill microorganisms and tumor cells and produce copious amounts of proinflammatory cytokines (13) . M2 macrophages tune inflammatory responses and adaptive Th1 immunity to promote angiogenesis as well as tissue remodeling and repair (13) . Previous studies have indicated that cluster of differentiation (CD)68 and CD163 are the most common TAM markers (14, 15) . CD68, first identified as a KP1 monoclonal antibody, recognizes epitopes in a wide variety of tissue macrophages, including Kupffer cells, germinal center, splenic and lamina propria macrophages, and granulocyte precursors (16) . CD163, first identified as an RM3/1 monoclonal antibody, was discovered during the search for specific differentiation markers for mononuclear phagocytes (17) . CD163 has been confirmed to be a phenotypic marker of M2 macrophages that can be used to distinguish M2 and M1 macrophages (17) .
The folate receptor (FR) family includes four members that bind folic acid with high affinity (18, 19) . The FRβ gene encodes glycosyl phosphatidylinositol-anchored endocytic receptors expressed in certain epithelial tissues, normal myeloid tissues and acute myelogenous leukemia (20) (21) (22) . FRβ expression has been reported in TAMs, which exhibit an M2-like functional profile and exert potent immunosuppressive functions within the tumor environment (18) .
In the present study the expression of CD68, CD163 and FRβ in TAMs from 105 HCC specimens was investigated using immunohistochemistry. The association between these markers and clinicopathological features in patients with HCC was also assessed.
Patients and methods

Patient characteristics.
A total of 105 patients with primary HCC were treated using hepatic partial resection at the Department of Digestive Surgery, Kagoshima University Graduate School of Medicine (Kagoshima, Japan) between January 1996 and December 2002. The patients comprised 83 men and 22 women, with a median age of 64.7 years. Of these patients, 19 patients tested positive for the hepatitis B surface antigen, 73 were positive for the antibody to HCV and 13 were negative for the two viruses. The mean tumor diameter was 46.4 mm (range 10-150 mm). Macroscopically, 67 cases (63.8%) had simple nodular tumors, whereas 38 cases (36.2%) comprised other types. Microscopically, 20 tumors (19.0%) were well-differentiated HCC, 74 tumors (70.5%) were moderately differentiated and 8 tumors (7.6%) were poorly differentiated. A total of 36 tumors had infiltrated blood vessels and 27 cases presented with intrahepatic metastasis. For comorbidities, 41 cases presented with hypertension, 34 cases with diabetes mellitus and 12 cases with hyperlipidemia (Table I) . Patients with a history of treatment for HCC and synchronous or metachronous multiple cancers in other organs were excluded from the present study. Follow-up data were obtained from all patients post-surgery, with a median follow-up time of 53 months.
Informed consent. The present study was approved by the Ethics Committees of the Graduate School of Medical and Dental Sciences, Kagoshima University (Kagoshima, Japan; registration number 25-39) and was conducted according to the Declaration of Helsinki. Written informed consent was obtained from each patient, including consent to publish and to report individual data from the participant.
Immunohistochemistry. Tissues were immersed into 10% neutral buffered formalin for 24 h at room temperature immediately after resection and then embedded with paraffin. Consecutive 4-µm sections were cut from each paraffin-embedded block. Sections were immunostained with anti-CD68 (cat. no. M0876; Dako; Agilent Technologies, Inc., Santa Clara, CA, USA), anti-CD163 (cat. no. Mob460; Diagnostic BioSystems, Inc., Pleasanton, CA, USA) and FRβ antibody, which was kindly provided by Professor Matsuyama, Department of Immunology, Graduate School of Medical and Dental Sciences, Kagoshima University (23) . Briefly, following blocking with 0.3% H 2 O 2 /methanol for 30 min at room temperature, specimens were blocked with PBS containing 5% normal horse serum (Vector Laboratories Inc., Burlingame, CA, USA) for 30 min at room temperature. Anti-CD68, anti-CD163 and FRβ antibodies were used at a dilution of 1:100. Following overnight incubation at 4˚C with the primary antibodies, specimens were briefly washed in PBS and incubated at room temperature for 30 min with polymer detection system used at 1:1 dilution (cat. no. 424132; Histofine simple stain MAX PO; Nichirei Biosciences, Tokyo, Japan). The specimens were washed with PBS and developed for 2 min at room temperature using diaminobenzidine solution (Dako; Agilent Technologies, Inc.). Specimens were subsequently washed with water and counterstained with Meyer's hematoxylin for 30 sec at room temperature (Sigma-Aldrich; Merck KGaA, Darmstadt, Germany).
Evaluation of CD68, CD163 and FRβ immunostaining.
To evaluate the results of immunohistochemical staining, the immunostained sections were scanned using a BX50-32 light microscope and DP71-SET-A digital camera (both Olympus Corporation, Tokyo, Japan) at a magnification of x40. The sections were analyzed with cellSens Standard software Data are presented as median ± standard deviation.
(v1.11; Olympus Corporation). The six fields of intra-tumor and peri-tumor lesions with the greatest staining intensity in each specimen were selected, the number positive cells in each field was counted manually using high power (x200 magnification) light microscopy and the mean number of positive cells for each specimen was calculated. The peri-tumoral The tumor stage and pathological parameters were determined according to the General Rules for the Clinical and Pathological Study of Primary Liver Cancer (24) . The overall survival (OS) was calculated from the date of resection to the date of mortality regardless of the cause. Recurrence-free survival (RFS) was calculated from the date of resection to the date that the tumor recurrence was diagnosed or from the date of resection to the last visit if recurrence was not diagnosed.
Statistical analysis. An unpaired t-test was used to evaluate continuous variables. Analysis of variance (ANOVA) was used to determine whether there was a significant difference between groups of tumor stage and histological differentiation. When ANOVA showed a significant result, the Tukey honest significance difference test was used to define between which groups there was a significant difference. The cumulative OS and RFS rates were calculated using the Kaplan-Meier method and tested using the Generalized Wilcoxon test. Data are presented as the mean ± standard deviation. Correlations were analyzed using Pearson's correlation coefficient. Statistical analyses were performed using the SPSS statistical software package (version 24; IBM Corp., Armonk, NY, USA). P<0.05 was considered to indicate a statistically significant difference.
Results
CD68, CD163 and FRβ expression in lesions.
Positive staining for CD68, CD163 and FRβ was assessed in intra-tumor and peri-tumor lesions, and was mainly observed in the cytoplasm of stroma cells. The majority of tumor cells and hepatic cells were negatively stained (Fig. 1) . Association between prognosis and CD68, CD163 and FRβ expression. Patients were divided into subgroups depending on the number of CD68 and CD163 cells observed and the CD163/68 ratio, as well as into FRβ positive or negative groups. The OS and RFS for the groups were then compared. No significant differences in OS and RFS were identified between groups (Figs. 3-6 ). When a cut-off value of 1.0 was set for the CD163/68 ratio, OS (for the lower ratio group was significantly shorter compared with the higher ratio group median survival 84.2 vs. 72.3 months; P=0.046; Fig. 7) . However, no significant differences in RFS were identified between the two groups (Fig. 7) . Data are presented as number, percent and median ± standard deviation, tested using the unpaired t-test. For the analysis of tumor stage and histological differentiation, analysis of variance was used followed by a Tukey honest significance difference test. 
Discussion
Monocytes are recruited from the circulation at sites of injury, inflammation, infection and malignancy, where they differentiate into tissue macrophages (25) . The expression of numerous myeloid lineage markers can change upon exposure to inflammatory mediators and secreted factors from invading cancer cells (26) . There have been a number of studies involving macrophage surface markers and various classes of macrophages have been proposed (16) (17) (18) . TAMs, which express CD68 and CD163 in HCC, were evaluated using immunohistochemistry. The significance of CD68 and CD163 positive cells in a cancer microenvironment is controversial. Previous studies have indicated that CD68 and CD163 are the most common TAM markers (14, 15) . CD68, as a pan-macrophage or M1 marker, and CD163 as an M2 marker, have frequently been used to evaluate and classify TAMs (14, 27) . The infiltration of CD68 and CD163 positive cells in tumors is correlated with poor patient prognosis in cancers, including hepatocellular, breast, bladder and ovarian cancer as well as hilar cholangiocarcinoma (8, (28) (29) (30) (31) . The results of the present study demonstrated that high expression of CD68 and CD163 was associated with worse outcome. However, Koelzer et al (26) , reported that strong infiltration was correlated with favorable clinicopathological features in colon cancer. They observed that 40% of all CD68 positive macrophages were CD163 positive, and 60% were inducible nitric oxide synthase (M1 macrophage marker) positive with double immunohistochemistry. In fact, a marked correlation between CD163 and CD68 was observed in the present study. These results may demonstrate that TAMs are not simply cells with single markers or restricted M1 or M2 phenotypes and that they are more diverse and heterogeneous, with cells exhibiting considerable plasticity driven by environmental factors. Additionally, organ type may influence the prognostic impact of macrophages (26) .
The correlation between the CD163/68 ratio and clinicopathological features was assessed. The ratio was significantly lower in patients with stage IV cancer, DCP abnormalities, infiltration to blood vessels and intrahepatic metastasis (Table IV) . The OS of the group with a CD163/68 ratio <1 was significantly shorter than that for the higher ratio group (Fig. 7) . A lower CD163/68 ratio appeared to be associated with worse prognosis in the present study. Komohara et al (32) examined the association between the CD163/68 ratio and the patient prognosis in glioma. They identified a significantly improved survival rate for patients with a lower CD163/68 ratio, and their results are in agreement with those of the present study. These results may also demonstrate that TAMs are diverse and heterogeneous and that the organ type influences the prognostic impact of macrophages.
The association between the number of FRβ positive cells, M2 macrophage markers, and the clinicopathological features was also evaluated. Nagai et al (33) and Nagayoshi et al (23) , demonstrated that all FRβ-expressing cells were CD68 positive macrophages in glioblastoma, that the expression of FRβ was limited to activated macrophages, and that TAM depletion by FRβ monoclonal antibody reduced tumor growth into C6 glioma xenografts in nude mice. Puig-Kröger et al (18) , also reported that FRβ was a marker for M2 macrophages. However, de Boer et al (34) , reported that FRβ status did not correlate with OS, RFS or other clinicopathological factors in colon, ovarian, and breast cancer, and concluded that FRβ positivity in tissue macrophages near an infiltrative tumor reflected not only a tumor-specific phenomenon but also an inflammatory process. The results of the current study also demonstrated that the number of FRβ positive cells was not correlated to the clinicopathological features. This is because FRβ positivity may reflect an inflammatory process, and our study group may possess not only tumor-specific but also inflammatory macrophages.
In conclusion, the present study on HCC demonstrated that high expression of CD68 and CD163 appeared to be associated with worse outcome. Particularly, a low CD163/68 ratio strongly correlated with worse results, and a CD163/68 ratio <1 was associated with worse prognosis. However, the number of FRβ positive cells was not correlated with the clinicopathological features. As immunohistochemistry can only measure one or two markers per sample, it may not fully reflect the complex factors involved. This is a limitation of our and a number of immunohistochemistry studies. More advanced studies using different technologies are expected, and further studies are required to determine the cross-interaction between diverse TAMs and the tumor microenvironment.
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